FAQ

varespladib methyl

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2011
02420092011

Related topics

Related topics

5 relations

Narrower (2)

A-002LY 315920

Broader (3)

AcetatesIndolesPhospholipase A2 Inhibitors

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
varespladib methyl
Indoles
Acetates
LY 315920
A-002
Phospholipase A2 Inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Phospholipase A2 enzymes and the risk of atherosclerosis.
Certain members of the phospholipase A(2) superfamily of enzymes have established causal involvement in atherosclerosis, thus at… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
Secretory phospholipase A(2) (sPLA(2)) represents a family of isoenzymes that participate in lipoprotein and inflammatory… (More)
Is this relevant?
2011
2011
Anti-Inflammatory Effects of Varespladib Methyl in Diabetic Patients with Acute Coronary Syndrome
Secretory phospholipase A2 group IIA (sPLA2−IIA) concentration and activity are associated with increased risk of cardiovascular… (More)
  • table 1
  • table 2
  • figure 3
  • figure 1
  • figure 2
Is this relevant?
2011
2011
Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.
AIMS To investigate the effects of secretory phospholipase A2 (sPLA(2)) inhibition on plasma lipoproteins. Secretory… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2011
2011
Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA…
The action of secretory phospholipase A2 (sPLA2) on lipoproteins may render them more susceptible to oxidation, thereby promoting… (More)
  • table 1
Is this relevant?
2010
2010
Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
OBJECTIVES The purpose of this study was to investigate the effects of varespladib on cardiovascular biomarkers in acute coronary… (More)
  • table 2
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2010
Review
2010
Varespladib methyl in cardiovascular disease.
IMPORTANCE OF THE FIELD The high risk of recurrent cardiovascular events amongst patients with cardiovascular disease receiving… (More)
Is this relevant?
Review
2010
Review
2010
Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes.
PURPOSE OF REVIEW Selective inhibitors of secretory phospholipase A2 and lipoprotein-associated phospholipase A2 are potential… (More)
Is this relevant?
2009
2009
Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease.
Varespladib methyl is an oral secretory phospholipase A2 inhibitor that is being developed by Anthera Pharmaceuticals Inc for the… (More)
Is this relevant?